ストックスクリーナーアプリを入手
0.6298
5.26%
-0.035
プレマーケット:
.61
-0.0198
-3.14%
Biofrontera Inc (BFRI) 最新ニュース
Actinic Keratosis Treatment Market SWOT Analysis by Leading Expert: Almirall, Biofrontera, Nestle - newstrail.com
biofrontera inc. revises proxy statement disclosure By Investing.com - Investing.com South Africa
biofrontera inc. revises proxy statement disclosure - Investing.com
Biofrontera Updates Proxy Statement for 2025 Meeting - TipRanks
Biofrontera Glycol-Free Skin Gel Added to FDA 'Orange Book;' Shares Rise - marketscreener.com
Biofrontera secures patent for Ameluz formulation until 2043 By Investing.com - Investing.com Canada
Biofrontera Inc. (BFRI) Propylene Glycol-Free Patent Gains FDA Recognition | BFRI Stock News - GuruFocus
Biofrontera announces inclusion of patent in FDA Orange Book - TipRanks
Biofrontera Inc. Announces Patent for Propylene Glycol-Free - GlobeNewswire
Biofrontera Secures 18-Year Patent Protection for Allergen-Free Ameluz Formula in FDA Orange Book - Stock Titan
Biofrontera stock hits 52-week low at $0.58 amid market challenges By Investing.com - Investing.com South Africa
Biofrontera stock hits 52-week low at $0.58 amid market challenges - Investing.com India
Biofrontera AG Faces Financial Uncertainty Amid Biofrontera Inc. Payment Issues - TipRanks
Biofrontera Receives Nasdaq Non-Compliance Notice - TipRanks
Roth Capital Decreases Earnings Estimates for Biofrontera - Defense World
Q2 Earnings Forecast for Biofrontera Issued By Roth Capital - Defense World
Biofrontera Inc. (NASDAQ:BFRI) Q1 2025 Earnings Call Transcript - Insider Monkey
Biofrontera (NASDAQ:BFRI) Price Target Lowered to $2.75 at Benchmark - Defense World
Biofrontera, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Benchmark cuts Biofrontera stock target to $2.75, keeps Buy rating By Investing.com - Investing.com Nigeria
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com - FinancialContent
Biofrontera (BFRI) Sees Price Target Reduction by Benchmark | BF - GuruFocus
Benchmark cuts Biofrontera stock target to $2.75, keeps Buy rating - Investing.com Australia
Biofrontera (BFRI) Target Price Trimmed After Lower Revenue Perf - GuruFocus
Biofrontera Inc. price target lowered to $2.75 from $7 at Benchmark - TipRanks
Biofrontera signals 2025 record revenue ambitions with new Ameluz patent and cost controls - MSN
Biofrontera Inc. (BFRI) Reports 9% Revenue Growth in Q1 2025 - GuruFocus
Earnings call transcript: Biofrontera Q1 2025 sees revenue rise, stock dips - Investing.com Nigeria
Earnings call transcript: Biofrontera Q1 2025 sees revenue rise, stock dips By Investing.com - Investing.com South Africa
Transcript : Biofrontera Inc., Q1 2025 Earnings Call, May 16, 2025 - marketscreener.com
BFRI Increases Q1 Revenue and Expands Market Presence | BFRI Sto - GuruFocus
Biofrontera extends Ameluz patent to 2043 for acne treatment By Investing.com - Investing.com Nigeria
Biofrontera Inc. reports Q1 EPS (47c) vs. ($2.88) last year - TipRanks
Biofrontera Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Biofrontera Inc. (BFRI) Sees Encouraging Revenue Growth in Q1 | - GuruFocus
Biofrontera Inc. (BFRI) Sees Encouraging Revenue Growth in Q1 | BFRI Stock News - GuruFocus
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update - The Manila Times
Biofrontera Inc. reports Q1 EPS (47c) vs. (71c) last year - TipRanks
Biofrontera (BFRI) Achieves Patent Approval and Advances Clinica - GuruFocus
Biofrontera Announces New Patent Protection On Ameluz Until 2043 - marketscreener.com
Biofrontera (BFRI) Achieves Patent Approval and Advances Clinical Trials | BFRI Stock News - GuruFocus
Biofrontera's Revised Ameluz Formulation Receives US Patent Approval - marketscreener.com
Biofrontera extends Ameluz patent to 2043 for acne treatment - Investing.com
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris - The Manila Times
Biofrontera Inc. announces patent protection on Ameluz until 2043 - TipRanks
Biofrontera Inc. faces Nasdaq delisting over share price By Investing.com - Investing.com Nigeria
Biofrontera Inc. faces Nasdaq delisting over share price - Investing.com Australia
1.38%
0.61%
大文字化:
|
ボリューム (24 時間):